Well, there is clearly a need for de-escalating therapy, de-escalating the intensity of systemic therapy, at least in part of the patients, in select patients, at least in patients who get a kind of deep response to neoadjuvant therapy, for which we are not necessarily in the position of pursuing an intense systemic therapy, a combination therapy for longer term. Intravesical therapy is pretty well suited to achieve this goal by providing a cure or consolidating a response on the local tumor of the local tumor into the bladder, at the same time sparing patients unnecessary extra toxicity which is coming from systemic therapy use or combination therapy used systemically in this patient population...
Well, there is clearly a need for de-escalating therapy, de-escalating the intensity of systemic therapy, at least in part of the patients, in select patients, at least in patients who get a kind of deep response to neoadjuvant therapy, for which we are not necessarily in the position of pursuing an intense systemic therapy, a combination therapy for longer term. Intravesical therapy is pretty well suited to achieve this goal by providing a cure or consolidating a response on the local tumor of the local tumor into the bladder, at the same time sparing patients unnecessary extra toxicity which is coming from systemic therapy use or combination therapy used systemically in this patient population. So the ideal setting that is emerging with intravesical therapy is a kind of consolidation therapy post an induction course of systemic therapy.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
